P04577 (ENV_HV2RO) Reviewed, UniProtKB/Swiss-Prot
Last modified April 3, 2013. Version 92. History...
Names and origin
|Protein names||Recommended name:|
Envelope glycoprotein gp160
|Organism||Human immunodeficiency virus type 2 subtype A (isolate ROD) (HIV-2) [Complete proteome]|
|Taxonomic identifier||11720 [NCBI]|
|Taxonomic lineage||Viruses › Retro-transcribing viruses › Retroviridae › Orthoretrovirinae › Lentivirus › Primate lentivirus group ›|
|Virus host||Homo sapiens (Human) [TaxID: 9606]|
|Sequence length||858 AA.|
|Sequence processing||The displayed sequence is further processed into a mature form.|
|Protein existence||Evidence at protein level|
General annotation (Comments)
The surface protein gp120 (SU) attaches the virus to the host lymphoid cell by binding to the primary receptor CD4. This interaction induces a structural rearrangement creating a high affinity binding site for a chemokine coreceptor like CXCR4 and/or CCR5. This peculiar 2 stage receptor-interaction strategy allows gp120 to maintain the highly conserved coreceptor-binding site in a cryptic conformation, protected from neutralizing antibodies. Since CD4 also displays a binding site for the disulfide-isomerase P4HB/PDI, a P4HB/PDI-CD4-CXCR4-gp120 complex may form. In that complex, P4HB/PDI could reach and reduce gp120 disulfide bonds, causing major conformational changes in gp120. TXN, another PDI family member could also be involved in disulfide rearrangements in Env during fusion. These changes are transmitted to the transmembrane protein gp41 and are thought to activate its fusogenic potential by unmasking its fusion peptide By similarity.
The surface protein gp120 is a ligand for CD209/DC-SIGN and CLEC4M/DC-SIGNR, which are respectively found on dendritic cells (DCs), and on endothelial cells of liver sinusoids and lymph node sinuses. These interactions allow capture of viral particles at mucosal surfaces by these cells and subsequent transmission to permissive cells. DCs are professional antigen presenting cells, critical for host immunity by inducing specific immune responses against a broad variety of pathogens. They act as sentinels in various tissues where they take up antigen, process it, and present it to T-cells following migration to lymphoid organs. HIV subverts the migration properties of dendritic cells to gain access to CD4+ T-cells in lymph nodes. Virus transmission to permissive T-cells occurs either in trans (without DCs infection, through viral capture and transmission), or in cis (following DCs productive infection, through the usual CD4-gp120 interaction), thereby inducing a robust infection. In trans infection, bound virions remain infectious over days and it is proposed that they are not degraded, but protected in non-lysosomal acidic organelles within the DCs close to the cell membrane thus contributing to the viral infectious potential during DCs' migration from the periphery to the lymphoid tissues. On arrival at lymphoid tissues, intact virions recycle back to DCs' cell surface allowing virus transmission to CD4+ T-cells. Virion capture also seems to lead to MHC-II-restricted viral antigen presentation, and probably to the activation of HIV-specific CD4+ cells By similarity.
The transmembrane protein gp41 (TM) acts as a class I viral fusion protein. Under the current model, the protein has at least 3 conformational states: pre-fusion native state, pre-hairpin intermediate state, and post-fusion hairpin state. During fusion of viral and target intracellular membranes, the coiled coil regions (heptad repeats) assume a trimer-of-hairpins structure, positioning the fusion peptide in close proximity to the C-terminal region of the ectodomain. The formation of this structure appears to drive apposition and subsequent fusion of viral and target cell membranes. Complete fusion occurs in host cell endosomes and is dynamin-dependent, however some lipid transfer might occur at the plasma membrane. The virus undergoes clathrin-dependent internalization long before endosomal fusion, thus minimizing the surface exposure of conserved viral epitopes during fusion and reducing the efficacy of inhibitors targeting these epitopes. Membranes fusion leads to delivery of the nucleocapsid into the cytoplasm By similarity.
The envelope glyprotein gp160 precursor down-modulates cell surface CD4 antigen by interacting with it in the endoplasmic reticulum and blocking its transport to the cell surface By similarity.
The gp120-gp41 heterodimer seems to contribute to T-cell depletion during HIV-1 infection. The envelope glycoproteins expressed on the surface of infected cells induce apoptosis through an interaction with uninfected cells expressing the receptor (CD4) and the coreceptors CXCR4 or CCR5. This type of bystander killing may be obtained by at least three distinct mechanisms. First, the interaction between the 2 cells can induce cellular fusion followed by nuclear fusion within the syncytium. Syncytia are condemned to die from apoptosis. Second, the 2 interacting cells may not fuse entirely and simply exchange plasma membrane lipids, after a sort of hemifusion process, followed by rapid death. Third, it is possible that virus-infected cells, on the point of undergoing apoptosis, fuse with CD4-expressing cells, in which case apoptosis is rapidly transmitted from one cell to the other and thus occurs in a sort of contagious fashion By similarity.
The gp120-gp41 heterodimer allows rapid transcytosis of the virus through CD4 negative cells such as simple epithelial monolayers of the intestinal, rectal and endocervical epithelial barriers. Both gp120 and gp41 specifically recognize glycosphingolipids galactosyl-ceramide (GalCer) or 3' sulfo-galactosyl-ceramide (GalS) present in the lipid rafts structures of epithelial cells. Binding to these alternative receptors allows the rapid transcytosis of the virus through the epithelial cells. This transcytotic vesicle-mediated transport of virions from the apical side to the basolateral side of the epithelial cells does not involve infection of the cells themselves By similarity.
The mature envelope protein (Env) consists of a homotrimer of non-covalently associated gp120-gp41 heterodimers. The resulting complex protrudes from the virus surface as a spike. There seems to be as few as 10 spikes on the average virion. Surface protein gp120 interacts with human CD4, CCR5 and CXCR4, to form a P4HB/PDI-CD4-CXCR4-gp120 complex. Gp120 also interacts with the C-type lectins CD209/DC-SIGN and CLEC4M/DC-SIGNR (collectively referred to as DC-SIGN(R)). Gp120 and gp41 interact with GalCer By similarity. Ref.2
Transmembrane protein gp41: Virion membrane; Single-pass type I membrane protein By similarity. Host cell membrane; Single-pass type I membrane protein By similarity. Host endosome membrane; Single-pass type I membrane protein Potential. Note: It is probably concentrated at the site of budding and incorporated into the virions possibly by contacts between the cytoplasmic tail of Env and the N-terminus of Gag By similarity.
Surface protein gp120: Virion membrane; Peripheral membrane protein By similarity. Host cell membrane; Peripheral membrane protein By similarity. Host endosome membrane; Peripheral membrane protein Potential. Note: The surface protein is not anchored to the viral envelope, but associates with the extravirion surface through its binding to TM. It is probably concentrated at the site of budding and incorporated into the virions possibly by contacts between the cytoplasmic tail of Env and the N-terminus of Gag By similarity.
Some of the most genetically diverse regions of the viral genome are present in Env. They are called variable regions 1 through 5 (V1 through V5). Coreceptor usage of gp120 is determined mainly by the primary structure of the third variable region (V3) in the outer domain of gp120. Binding to CCR5 involves a region adjacent in addition to V3 By similarity.
The 17 amino acids long immunosuppressive region is present in many retroviral envelope proteins. Synthetic peptides derived from this relatively conserved sequence inhibit immune function in vitro and in vivo By similarity.
Specific enzymatic cleavages in vivo yield mature proteins. Envelope glycoproteins are synthesized as a inactive precursor that is heavily N-glycosylated and processed likely by host cell furin in the Golgi to yield the mature SU and TM proteins. The cleavage site between SU and TM requires the minimal sequence [KR]-X-[KR]-R By similarity.
Palmitoylation of the transmembrane protein and of Env polyprotein (prior to its proteolytic cleavage) is essential for their association with host cell membrane lipid rafts. Palmitoylation is therefore required for envelope trafficking to classical lipid rafts, but not for viral replication By similarity.
Some HIV-2 isolates have been described that can infect cells independently of CD4, using CXCR4 as primary receptor. These isolates may have an exposed coreceptor binding site.
Sequence annotation (Features)
|Feature key||Position(s)||Length||Description||Graphical view||Feature identifier|
|Signal peptide||1 – 19||19||Potential|
|Chain||20 – 858||839||Envelope glycoprotein gp160||PRO_0000239503|
|Chain||20 – 511||492||Surface protein gp120 By similarity||PRO_0000038449|
|Chain||512 – 858||347||Transmembrane protein gp41 By similarity||PRO_0000038450|
|Topological domain||20 – 679||660||Extracellular Potential|
|Transmembrane||680 – 700||21||Helical; Potential|
|Topological domain||701 – 858||158||Cytoplasmic Potential|
|Region||110 – 162||53||V1|
|Region||163 – 205||43||V2|
|Region||305 – 339||35||V3|
|Region||399 – 419||21||V4|
|Region||462 – 469||8||V5|
|Region||512 – 532||21||Fusion peptide Potential|
|Region||575 – 591||17||Immunosuppression By similarity|
|Region||657 – 678||22||MPER; binding to GalCer By similarity|
|Coiled coil||624 – 645||22||Potential|
|Motif||707 – 710||4||YXXV motif; contains endocytosis signal By similarity|
|Motif||857 – 858||2||Di-leucine internalization motif By similarity|
|Site||?511 – ?512||2||Cleavage; by host furin Potential|
Amino acid modifications
|Lipidation||773||1||S-palmitoyl cysteine; by host By similarity|
|Glycosylation||34||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||67||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||76||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||119||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||120||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||151||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||166||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||179||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||192||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||193||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||196||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||206||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||238||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||241||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||248||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||272||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||278||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||289||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||300||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||310||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||367||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||371||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||400||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||410||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||447||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||463||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||466||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||611||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||620||1||N-linked (GlcNAc...); by host Potential|
|Glycosylation||636||1||N-linked (GlcNAc...); by host Potential|
|Disulfide bond||41 ↔ 54||By similarity|
|Disulfide bond||98 ↔ 214||By similarity|
|Disulfide bond||105 ↔ 205||By similarity|
|Disulfide bond||110 ↔ 163||By similarity|
|Disulfide bond||227 ↔ 257||By similarity|
|Disulfide bond||237 ↔ 249||By similarity|
|Disulfide bond||305 ↔ 340||By similarity|
|Disulfide bond||392 ↔ 446||By similarity|
|Disulfide bond||399 ↔ 419||By similarity|
|Sequence conflict||312||1||T → I in AAB00770. Ref.1|
|||"Genome organization and transactivation of the human immunodeficiency virus type 2."|
Guyader M., Emerman M., Sonigo P., Clavel F., Montagnier L., Alizon M.
Nature 326:662-669(1987) [PubMed] [Europe PMC] [Abstract]
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA].
|||"DC-SIGN interactions with human immunodeficiency virus type 1 and 2 and simian immunodeficiency virus."|
Pohlmann S., Baribaud F., Lee B., Leslie G.J., Sanchez M.D., Hiebenthal-Millow K., Munch J., Kirchhoff F., Doms R.W.
J. Virol. 75:4664-4672(2001) [PubMed] [Europe PMC] [Abstract]
Cited for: INTERACTION OF SURFACE PROTEIN GP120 WITH HOST CD209/DC-SIGN.
Strain: Isolate rod10.
|||"Human immunodeficiency virus type 2."|
Reeves J.D., Doms R.W.
J. Gen. Virol. 83:1253-1265(2002) [PubMed] [Europe PMC] [Abstract]
Cited for: REVIEW.
|M15390 Genomic DNA. Translation: AAB00770.1.|
X05291 Genomic RNA. Translation: CAA28914.1.
|PIR||VCLJG2. C26262. |
3D structure databases
|SMR||P04577. Positions 61-487, 538-660. |
Protocols and materials databases
Family and domain databases
|Gene3D||126.96.36.199. 2 hits. |
|InterPro||IPR000777. HIV1_GP160. |
|Pfam||PF00516. GP120. 1 hit. |
PF00517. GP41. 1 hit.
|SUPFAM||SSF56502. GP120. 1 hit. |
|Accession||Primary (citable) accession number: P04577|
|Entry status||Reviewed (UniProtKB/Swiss-Prot)|
|Annotation program||Viral Protein Annotation Program|